Please use this identifier to cite or link to this item:
|Title:||Trametinib plus dabrafenib: Targeting RAS-MAPK pathway for BRAF V600-mutant melanoma|
|Source:||Ku, C.-S. (2012-10). Trametinib plus dabrafenib: Targeting RAS-MAPK pathway for BRAF V600-mutant melanoma. Gastric and Breast Cancer 11 (4) : 208-210. ScholarBank@NUS Repository. https://doi.org/10.2122/gbc.2012.0251|
|Abstract:||Genetic and epigenetic changes and signalling pathways activation drive carcinogenesis, tumor growth and metastasis. One of several signalling pathways involved in ∼ 20% of cancers is the RAF-MEK-ERK pathway that is activated through RAS oncoproteins or mutations in these genes . In 66% of melanomas and in lower frequency for other cancer types, activating mutations in BRAF have been found. Despite progression-free survival and overall survival benefit with vemurafenib and dabrafenib that are BRAF and MEK inhibitors of BRAFV600-mutant advanced melanomas respectively [2,3], resistance occurs in more than 50% of patients. In a more recent phase 1 and 2 study, the BRAF-MEK complex of dabrafenib plus trametinib inhibitors has been evaluated for metastatic melanoma patients with BRAF V600 mutations . Can this combined treatment decrease resistance for improving survival of these patients?|
|Source Title:||Gastric and Breast Cancer|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Feb 15, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.